INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

NCT ID: NCT06965504

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-01
• Study Completion Date: 2028-06-01

Brief Summary

The study will evaluate if Impella 5.5® support in heart failure reduced ejection fraction (HFrEF) patients presenting with decompensated heart failure (HF) and cardiogenic shock will facilitate the initiation and optimization of guideline directed medical therapy (GDMT) during the hospital stay and post-discharge.

Detailed Description

This is a prospective, single arm, multi-center, post-market, on-label study. Patients presenting with HFrEF who are not on adequate GDMT and who are presenting with heart failure cardiogenic shock will be evaluated for inclusion. The study objectives are to evaluate the impact of Impella 5.5 support on GDMT up-titration during support, at discharge, and at 90-days post-discharge and to evaluate the feasibility of Impella 5.5 combined with optimal GDMT to improve heart recovery in patients with decompensated heart failure. Outcomes will be measured up to one-year post-hospital discharge.

Conditions

Heart Failure; Cardiogenic Shock; Reduced Ejection Fraction Heart Failure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm study

This is a single arm study.

Group Type: OTHER

Impella 5.5 SmartAssist

Intervention Type: DEVICE

The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).

Interventions

Impella 5.5 SmartAssist

The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 and < 75 years

2. Subject has signed the Informed Consent

3. LVEF ≤ 40%

4. History of HF <5 years

5. Subject is presenting with decompensated heart failure and meets one of the following cardiogenic shock criteria:

1. Sustained episode of systolic blood pressure ≤ 90 mmHg for at least 30 minutes or need for vasoactive agents to maintain such blood pressure.

2. Or serum lactate > 2 mmol/L

3. Or a cardiac index (CI) < 2.2 L/min/m2 determined to be secondary to cardiac dysfunction, in the absence of hypovolemia

4. Or required support with an intra-aortic balloon pump (IABP)

6. Subject has inadequate heart failure GDMT based on the most recent outpatient prescription prior to index admission as determined by the treating cardiologist and the Eligibility Committee, defined as:

1. On 2 or less of the evidence-based GDMT (BB, MRA, SGLT2i, and RASi)

2. If on β-blocker and RASi, at least one of the two medications is <50% of maximal dose.

Exclusion Criteria

1. Underlying unmodifiable conditions that limit initiation of GDMT prior to enrollment, including but not limited to:

1. Drug allergies or hypersensitivities to HF GDMT medications, unless alternative can be identified.

Drug allergy/hypersensitivity is an immune-mediated reaction to a medication. Adverse reactions must be a result of immune or inflammatory cell stimulations by the mеԁiсаtion:

2. Known bilateral renal artery stenosis

3. Type 1 diabetes

4. 2nd or 3rd degree AV block, unless pacemaker is in place

5. Angioedema, hereditary or idiopathic

6. Pregnancy, known or confirmed by a pregnancy test if of child bearing potential.

2. Cardiogenic shock due to myocardial infarction prior to enrollment

3. Mixed shock, septic shock, or shock from non-cardiac origins

4. Severe Cardiogenic Shock, defined as meeting one or more of the below prior to enrollment:

1. SCAI stage E per Study Definition (Appendix C)

2. Serum lactate > 8mmol/L

3. On mechanical circulatory support (not including IABP) or on mechanical ventilation for non-procedural reasons.

4. Experiencing pulseless electrical activity (PEA) or refractory ventricular tachycardia (VT)/ventricular fibrillation (VF)

5. Severe acidosis (pH < 7.2 or bicarbonate < 10mEq/L)

5. In cardiac arrest prior to enrollment

6. Revascularization or cardiac surgery within 90-days of the index hospitalization date or decision to undergo revascularization or cardiac surgery made prior to enrollment.

7. Inflammatory and infiltrative cardiomyopathy (CM) including myocarditis, restrictive CM, constrictive pericarditis, or hypertrophic CM including sarcoidosis and amyloidosis.

8. Adult congenital heart disease without appropriate surgical correction

9. Structural or anatomical abnormalities that cannot be modified as determined by the treating cardiologist, including severe primary mitral regurgitation (MR) .

10. Severe RV dysfunction, per Study Definition (Appendix C), requiring mechanical or inotropic support prior to enrollment.

11. Severe dilatation of the LV with LVEDD greater than 8.0cm

12. History of heart transplant or listed for heart transplant prior to enrollment.

13. Planned to be implanted with a permanent VAD within 90-days of the index hospitalization date.

14. Continuous outpatient inotropic support prior to the index hospitalization date.

15. Planned to pursue palliative care or hospice, or life expectancy of less than 2 years due to non-cardiac illness at the time of index hospitalization date.

16. ICD upgrade to BiV, or implantation of CRT within 30-days of the index hospitalization date.

17. Currently on dialysis, or has pre-existing end-stage chronic kidney disease (stage 4 or above), or has hereditary, infectious, or autoimmune nephropathy.

18. Pre-existing liver dysfunction defined as: presence of liver cirrhosis or alcoholic hepatitis, or presence of acute liver failure or acute hepatitis not due to cardiogenic shock.

19. Pre-existing pulmonary disease requiring home oxygen

20. History of stroke or intracranial hemorrhage ≤ 90 days of the index hospitalization date, or a history of cerebrovascular disease with significant (> 80%) uncorrected carotid stenosis, or any permanent neurological deficit with mRS score >2.

21. Any contraindication that precludes placing an Impella 5.5®, including but not limited to:

1. Aortic valve stenosis/calcification with orifice area ≤0.6cm2 or aortic insufficiency of any grade greater than mild on pre-procedure echocardiography.

2. Presence of mechanical aortic valve or heart constrictive device.

3. Thrombus in the left atrium or ventricle.

4. Infection of the planned procedural access site or suspected systemic active infection.

5. Severe arterial disease precluding placement of Impella.

6. Presence of Atrial or Ventricular Septal Defect (including post-infarct VSD)

7. Left ventricular rupture

8. Cardiac tamponade I. Combined cardiorespiratory failure

22. Known contraindication to heparin (i.e., heparin induced thrombocytopenia (HIT)) or intolerance to anticoagulant or antiplatelet therapies.

23. Allergies or contraindications to contrast agents unless can be adequately medicated.

24. History of bleeding diathesis or known coagulopathy, any GU or GI bleed within 90-days of the index hospitalization date or will refuse blood transfusions.

25. Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures.

26. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not met its primary endpoint.

27. Subject belongs to a vulnerable population, such as such as prisoners, individuals with impaired decision making, or economically or educationally disadvantaged persons.

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Johnson & Johnson

INDUSTRY

Sponsor Role: collaborator

Abiomed Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adam DeVore, MD, MHS

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Tampa General Hospital

Tampa, Florida, United States

Abbott Northwestern

Minneapolis, Minnesota, United States

Rutgers-Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States

University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Centennial Medical Center

Nashville, Tennessee, United States

Countries

United States

Central Contacts

Roberta Chapman, MD, FACC, FACP, FHFSA

Role: CONTACT

rchapm11@its.jnj.com

+1 978-882-8421

Stacie Hallaway

Role: CONTACT

shallawa@its.jnj.com

839-216-3087

Facility Contacts

Courtney Nicholas, BS RN, CCRP, CVRN-BC

Role: primary

courtneynicholas@tgh.org

813-844-4914

Juilanne Feola

Role: primary

julianne.feola@allina.com

612-863-6066

Manisha Bajpai, MD

Role: primary

bajpaima@rwjms.rutgers.edu

732-258-3649

Alyson Brown

Role: primary

alyson.brown@pennmedicine.upenn.edu

215-662-2128

Kristen Kuhn

Role: primary

kristen.kuhn2@hcahealthcare.com

615.982.0640

Other Identifiers

INTeGRATE

Identifier Type: -

Identifier Source: org_study_id